All patients
Age > 65y BCLC B BCLC C ECOG 0 ECOG 1 Gender, female Gender, male viral status HBV viral status HCV viral status uninfected
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mHCC - 1st line (L1), anti-PD-(L)1 vs. lenvatinib, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results LEAP 002, 2023 0.84 [0.71; 1.00]
0.84 [0.71 ; 1.00 ] LEAP 002, 2023 1 0% 794 NA not evaluable progression or deaths (PFS)detailed results LEAP 002, 2023 0.87 [0.74; 1.03]
0.87 [0.74 ; 1.03 ] LEAP 002, 2023 1 0% 794 NA not evaluable AE (any grade)detailed results LEAP 002, 2023 1.22 [0.59; 2.52]
1.22 [0.59 ; 2.52 ] LEAP 002, 2023 1 0% 790 NA not evaluable AE (grade 3-4)detailed results LEAP 002, 2023 1.22 [0.92; 1.62]
1.22 [0.92 ; 1.62 ] LEAP 002, 2023 1 0% 790 NA not evaluable AE leading to death (grade 5)detailed results LEAP 002, 2023 1.34 [0.30; 6.01]
1.34 [0.30 ; 6.01 ] LEAP 002, 2023 1 0% 790 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results LEAP 002, 2023 1.84 [1.22; 2.78]
1.84 [1.22 ; 2.78 ] LEAP 002, 2023 1 0% 790 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 20:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 131
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563